Price Check On Drug Ads: Would Revealing Costs Help Patients Control Spending?
As part of his plan to tamp down drug pricing, President Donald Trump wants pharmaceutical companies to provide cost information in drug ads — just like side effects.
Drugs
781 - 800 of 1,288 Results
-
-
Addiction Medicine Mostly Prescribed To Whites, Even As Opioid Deaths Rose Among Blacks
A study looked at who gets Suboxone prescriptions and found that whites are almost 35 times more likely to get the addiction treatment than African Americans.
-
The Money And Politics Of Prescription Drugs: What You Need To Know
America spends about as much on prescription drugs as all the revenues of the three big car makers combined. Tracking where the money goes is hard. PolitiFact has some charts to help.
-
Drug Industry Patents Go Under Senate Judiciary Committee’s Microscope
During a hearing Tuesday, panel members focused on how drug companies have used patents to allegedly protect their competitive edge and profits.
By Rachel Bluth -
CBO’s Report On Single-Payer Health Care Holds More Questions Than Answers
The Congressional Budget Office report does clearly communicate that shifting to this type of health system would be a complicated process.
-
Is Insulin’s High Cost Keeping Diabetes Patients From Taking Their Medicine?
An estimated 1.25 million Americans have Type 1 diabetes and cannot live without insulin. Sen. Kamala Harris’ claim that 1 in 4 diabetes patients cannot afford their insulin is a shockingly high number, so we decided to dig into the sparse data.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
Newsom: California Leads On Prescription Drugs
California Gov. Gavin Newsom claims that his state is “leading the nation in holding drug companies accountable and fighting prescription drug prices.” Is that really the case?
-
Klobuchar Wants To Stop ‘Pay-For-Delay’ Deals That Keep Drug Prices High
It’s as shady as it sounds.
-
Pain Clinics’ Doctors Needlessly Tested Hundreds Of Urine Samples, Court Records Show
Whistleblower lawsuits accuse Tennessee chain of bilking millions from Medicare for unnecessary urine drug tests.
By Fred Schulte -
Amid Opioid Prescriber Crackdown, Health Officials Reach Out To Pain Patients
After dozens of health care workers were charged with illegally prescribing opioids in Appalachia, local health agencies are trying to make sure chronic pain patients don't fall through the cracks.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
Mulvaney: Trump Brought Down Drug Prices For The First Time In 50 Years
It’s "within spitting distance of something that’s true," said one health economist. But our fact check found it wasn't quite there.
-
The Blame Game: Everyone And No One Is Raising Insulin Prices
During Wednesday’s House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade’s 300% price increase, frustrating congressional representatives.
By Rachel Bluth -
Can Someone Tell Me What A PBM Does?
The Senate Finance Committee’s third drug-pricing hearing focused on pharmacy benefit managers, and was more of a fact-finding mission on how these companies operate than a debate about policy proposals.
By Rachel Bluth -
Consumers Rejected Drug Plan That Mirrors Trump Administration Proposal
What to know about PBMs and rebates ahead of the Senate drug price hearing on — you guessed it — PBMs.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
-
Doughnut Hole Is Gone, But Medicare’s Uncapped Drug Costs Still Bite Into Budgets
Beneficiaries pay 25 percent of the price of their brand-name drugs until they reach $5,100 in out-of-pocket costs. After that, their obligation drops to 5 percent. But it never disappears.
-
Analysis: Why Americans Shouldn’t Feel Grateful For $137 Insulin
Only by the bizarre logic of the U.S. pharmaceutical industry does this drug count as any kind of generic.